← 홈

자가면역·염증성 · IL-17A

7개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 7개
AntibodySHOTFDACuratedFDABiologicNovartisApproved

secukinumab (Cosentyx)

Psoriasis, psoriatic arthritis, ankylosing spondylitis · IL-17A

#IL-17A#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 78.1%임상시험 153상태 APPROVED
AntibodyBNovartisApproved

AIN457 (Secukinumab, Secukinumab (AIN457))

Psoriatic Arthritis · Moderate to Severe Plaque-type Psoriasis

#ModeratetoSeverePlaque-typePsori#Antibody#Approved#인기#항체+4
효능 ORR 53%임상시험 98상태 ACTIVE
AntibodyBNovartisPhase 3

secukinumab (AIN457, AIN457 (secukinumab))

Asthma · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Phase3#인기#항체+4
효능 ORR 53%임상시험 95상태 ACTIVE
AntibodyEli Lilly and CompanyApproved

Ixekizumab (Ixekizumab)

Psoriasis; Atopic Dermatitis · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Approved#인기#항체+5
임상시험 53상태 RECRUITING
AntibodystaleNovartis PharmaceuticalsPreclinical

Secikinumab (Secikinumab)

Axial Spondylarthritis (axSpA); Secukinumab · Psoriasis

#Psoriasis#Antibody#Preclinical#항체#면역항체+4
임상시험 2상태 ACTIVE
AntibodystaleNovartisApproved

Secukinumab 150 milligram [Cosentyx] (Secukinumab 150 milligram [Cosentyx])

Axial Spondyloarthritis; Ankylosing Spondylitis · Axial Spondyloarthritis

#AxialSpondyloarthritis#Antibody#Approved#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleAbbViePreclinical

adalimumab (Humira, adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate)

Immunoclassification; Psoriasis · Immunoclassification

#Immunoclassification#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 RECRUITING